Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Gastrointestinal 1Breast 1

Conditions

Prostatic Neoplasms 2Urinary Bladder Neoplasms 1Neoplasm Metastasis 1

Interventions

Docetaxel 78Radiotherapy 73Prednisone 66Leuprolide 51Goserelin 49Gemcitabine 49Cisplatin 48bicalutamide 46enzalutamide 43Androgen Antagonists 36pembrolizumab 32Abiraterone Acetate 31Mitomycin 29acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 28Magnetic Resonance Spectroscopy 28Carboplatin 27Flutamide 25Nivolumab 24Triptorelin Pamoate 23Sunitinib 23apalutamide 22Radiation 22Doxorubicin 20darolutamide 19abiraterone 18Gonadotropin-Releasing Hormone 18cabozantinib 17atezolizumab 16Specimen Handling 16Radiosurgery 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × ferumoxtran-10 × Genitourinary × Clear all
NCT04261777 2026-04-28

Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients

Saving Patients' Lives Medical B.V.

Phase 3 Terminated
172 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00622973 2011-10-12

USPIO-enhanced and Diffusion-weighted MRI for the Detection of Pelvic Lymph Node Metastases

Insel Gruppe AG, University Hospital Bern

Phase 3 Completed
130 enrolled
Genitourinary

Urinary Bladder Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡